Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05233072
Active, not recruiting Not applicable

Prognostic Impact of Neopterin on Resumption of Walking After a Fracture of the Upper Neck of the Femur in the Elderly

NCT05233072 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Started
2022-05-16
Last updated
2025-02-17

Condition(s) studied

Fracture of Neck of FemurResumption of Walking

Investigational drug(s) / intervention(s)

Blood sample

Blood sample: Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0

Study summary

Society faces a major challenge with the management of the health and socio-economic burden caused by acute physical stress in the older population (\>75 years). In particular, hip fracture (HF) represents a major health care preoccupation, affecting 1.6 M patients worldwide, resulting in a significant drop of life quality and autonomy. Nowadays, this trauma is still associated with a poor outcome of 20-30% one-year mortality in the elderly. This emphasizes the value of assessing biological factors that may predict clinical outcome after HF. The preliminary work pinpoints a central role of neopterin in loss of autonomy and death. Using HF as an acute stress model that accelerates the progressive course of aging, the aim is to validate neopterin as a predictive biomarker of pernicious clinical outcomes.

Eligibility

Sex
ALL
Min age
75 Years
Max age
110 Years
Healthy volunteers
No
Inclusion Criteria: For both arms: * age over 75 * affiliated to health insurance system * written informed consent For arm 'Fracture': * patient with a fracture of the upper neck of the femur * hospitalized in emergency in a 'UPOG' unit For arm 'control': * hospitalized patient without any acute clinical event Exclusion Criteria: For both arms: * polytrauma * pathological bone or prothesis fracture * patient affiliated to 'Aide Médical de l'Etat - AME' insurance * patient with immunosuppressant treatment (including corticotherapy over 5 mg/d) * patient with active solid cancer or malignant haemopathy * patient with auto-immune disease * refusal to participate in research For arm 'Fracture': * patient under justice protection measure except tutorship and guardianship For arm 'control': * severe neurocognitive disorders (MMS \< 15) * fracture of the upper neck of the femur in the last year * patient under justice protection measure

Primary outcome measure(s)

  • Resumption of walking with or without help — Day 30
    Speed walk over 4 meters

Trial sites (1)

FacilityCityRegionStatus
GH Pitié-Salpêtrière / Service de gériatrie Paris Île-de-France Region

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05233072 on ClinicalTrials.gov ↗ ← All trials in France